Phase I study of 99mTc-ADAPT6, a scaffold protein-based probe for visualization of HER2 expression in breast cancer

Published on Apr 1, 2021in The Journal of Nuclear Medicine7.887
· DOI :10.2967/JNUMED.120.248799
Olga Bragina4
Estimated H-index: 4
(RAS: Russian Academy of Sciences),
Emma von Witting4
Estimated H-index: 4
(KTH: Royal Institute of Technology)
+ 13 AuthorsVladimir Tolmachev61
Estimated H-index: 61
(Uppsala University)
Radionuclide molecular imaging of human epidermal growth factor (HER2) expression may be helpful to stratify breast and gastroesophageal cancer patients for HER2-targeting therapies. ADAPTs (albumin-binding domain derived affinity proteins) are a new type of small (46-59 amino acids) proteins useful as probes for molecular imaging. The aim of this first-in-human study was to evaluate biodistribution, dosimetry, and safety of the HER2-specific 99mTc-ADAPT6. METHODS: Twenty-nine patients with primary breast cancerwere included. In 22 patients with HER2-positive (n = 11) or HER2-negative (n = 11) histopathology an intravenous injection with 385±125 MBq 99mTc-ADAPT6 was performed, randomized to an injected protein mass of either 500 µg (n = 11) or 1000 µg (n = 11). Planar scintigraphy followed by SPECT imaging was performed after 2, 4, 6 and 24 h. An additional cohort (n = 7) was injected with 165±29 MBq (injected protein mass 250 µg) and imaging was performed after 2 h only. RESULTS: Injections of 99mTc-ADAPT6 at all injected mass levels were well tolerated and not associated with adverse effects. 99mTc-ADAPT6 cleared rapidly from blood and most other tissues. The normal organs with the highest accumulation were kidney, liver and lung. Effective doses were 0.009±0.002 and 0.010±0.003 mSv/MBq for injected protein masses of 500 and 1000 µg, respectively. Injection of 500 µg resulted in excellent discrimination between HER2-positive and HER2-negative tumors already 2 h after injection (tumor-to-contralateral breast ratio was 37±19 vs 5±2, p<0.01). The tumor-to-contralateral breast ratios for HER2-positive tumors were significantly (p<0.05) higher for injected mass of 500 µg than for both 250 and 1000 µg. CONCLUSION: Injections of 99mTc-ADAPT6 are safe and associated with low absorbed and effective doses. Protein dose of 500 µg is preferable for discrimination between tumors with high and low expression of HER2. Further studies are justified to evaluate if 99mTc-ADAPT6 can be used as an imaging probe for stratification of patients for HER2-targeting therapy in the areas where PET imaging is not readily available.
📖 Papers frequently viewed together
1 Citations
146 Citations
#1Vittorio BrigantiH-Index: 5
#2Vincenzo CuccurulloH-Index: 14
Last. Luigi MansiH-Index: 23
view all 4 authors...
BACKGROUND: Pancreatic Neuroendocrine Tumors (PNETs) are rare neoplasms, sporadic or familial, even being part of a syndrome. Their diagnosis is based on symptoms, hormonal disorders or may be fortuitous. The role of Nuclear Medicine is important, mainly because of the possibility of a theranostic strategy. This approach is allowed by the availability of biochemical agents, which may be labeled with radionuclides suitable for diagnostic or therapeutic purposes, showing almost identical pharmacok...
4 CitationsSource
#1Frederike Bensch (UG: University of Groningen)H-Index: 9
#2Adrienne H. Brouwers (UG: University of Groningen)H-Index: 36
Last. Carolien P. Schröder (UG: University of Groningen)H-Index: 29
view all 8 authors...
Background Up-to-date information on human epidermal growth factor receptor 2 (HER2) status in breast cancer (BC) is important, as expression can vary during the course of the disease, necessitating anti-HER2 therapy adjustments. Repeat biopsies, however, are not always possible. In this feasibility trial we assessed whether 89Zr-trastuzumab PET could support diagnostic understanding and aid clinical decision making, when HER2 status could not be determined by standard work up. Additionally, HER...
33 CitationsSource
#1Ahmet KrasniqiH-Index: 8
Last. Vladimir Tolmachev (Uppsala University)H-Index: 61
view all 8 authors...
Imaging of expression of therapeutic targets may enable patients' stratification for targeted treatments. The use of small radiolabeled probes based on the heavy-chain variable region of heavy-chai ...
55 CitationsSource
#1Gary A. Ulaner (Cornell University)H-Index: 28
#2Serge K. Lyashchenko (Cornell University)H-Index: 21
Last. Joseph A. O'Donoghue (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 46
view all 10 authors...
: In what we believe to be a first-in-human study, we evaluated the safety and dosimetry of 89Zr-pertuzumab PET/CT for human epidermal growth factor receptor 2 (HER2)-targeted imaging in patients with HER2-positive breast cancer. Methods: Patients with HER2-positive breast cancer and evidence of distant metastases were enrolled in an institutional review board-approved prospective clinical trial. Pertuzumab was conjugated with deferoxamine and radiolabeled with 89Zr. Patients underwent PET/CT wi...
62 CitationsSource
#1Gary A. Ulaner (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 12
#2David M. HymanH-Index: 66
Last. Jorge A. CarrasquilloH-Index: 77
view all 5 authors...
PurposeThe aim of this study was to determine if imaging with 89Zr-trastuzumab, a human epidermal growth factor receptor 2 (HER2)–targeting PET tracer, can detect HER2-positive metastases in patients with HER2-negative primary breast cancer.MethodsAs part of an institutional review board–approved, p
40 CitationsSource
#1Angela N. Bartley (Vandy: Vanderbilt University)H-Index: 9
#2Mary Kay Washington (Vandy: Vanderbilt University)H-Index: 63
Last. Jaffer A. Ajani (Vandy: Vanderbilt University)H-Index: 122
view all 15 authors...
ContextERBB2 (erb-b2 receptor tyrosine kinase 2 or HER2) is currently the only biomarker established for selection of a specific therapy for patients with advanced gastroesophageal adenocarcinoma (GEA). However, there are no comprehensive guidelines for the assessment of HER2 in patients with GEA.ObjectivesTo establish an evidence-based guideline for HER2 testing in patients with GEA, formalize the algorithms for methods to improve the accuracy of HER2 testing while addressing which patients and...
132 CitationsSource
#1Richard Laforest (WashU: Washington University in St. Louis)H-Index: 47
#2Suzanne E. Lapi (WashU: Washington University in St. Louis)H-Index: 24
Last. Farrokh Dehdashti (WashU: Washington University in St. Louis)H-Index: 82
view all 12 authors...
Purpose The purpose of the present study is to evaluate safety, human radiation dosimetry, and optimal imaging time of [89Zr]trastuzumab in patients with HER2-positive breast cancer.
60 CitationsSource
#1Geraldine Gebhart (ULB: Université libre de Bruxelles)H-Index: 10
#2Laetitia E. Lamberts (UMCG: University Medical Center Groningen)H-Index: 13
Last. Patrick Flamen (ULB: Université libre de Bruxelles)H-Index: 39
view all 20 authors...
BACKGROUND: Only human epidermal growth factor receptor (HER)2 status determined by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) has been validated to predict efficacy of HER2-targeting antibody-drug-conjugate trastuzumab emtansine (T-DM1). We propose molecular imaging to explore intra-/interpatient heterogeneity in HER2 mapping of metastatic disease and to identify patients unlikely to benefit from T-DM1. PATIENTS AND METHODS: HER2-positive mBC patients with IHC3+ or...
175 CitationsSource
(68)Ga-ABY-025 is a radiolabeled Affibody molecule for in vivo diagnosis of human epidermal growth factor receptor 2 (HER2)-positive breast cancer tumors with PET. The aim of the present work was to measure the biodistribution and estimate the radiation dosimetry of (68)Ga-ABY-025 for 2 different peptide mass doses in a single group of patients using dynamic and serial whole-body PET/CT.Eight patients with metastatic breast cancer were included. Each patient underwent an abdominal 45-min dynamic...
52 CitationsSource
#1Geraldine Gebhart (ULB: Université libre de Bruxelles)H-Index: 10
#2Patrick Flamen (ULB: Université libre de Bruxelles)H-Index: 39
Last. Zena Wimana (ULB: Université libre de Bruxelles)H-Index: 8
view all 5 authors...
Since the approval of trastuzumab, a humanized monoclonal antibody against the extracellular domain of human epidermal growth factor receptor 2 (HER2), 3 other HER2-targeting agents have gained regulatory approval: lapatinib, pertuzumab, and trastuzumab-emtansine. These agents have revolutionized the management of HER2-positive breast cancer, highlighting the concept that targeted therapies are successful when patients exhibit tumor-selective expression of a molecular target-in this case, HER2. ...
27 CitationsSource
Cited By8
Background. null null null The chief goal in assessing the Her2/neu status in clinical practice is to identify indications for targeted therapy. The main methods for determining the Her2/neu status are an immunohistochemical method and fluorescence in situ hybridization (FISH); however, despite their widespread use, they have a number of significant disadvantages. Over the past few years, radionuclide diagnosis using a new class of alternative scaffold proteins that meet all the requirements for...
#1O. D. Bragina (RAS: Russian Academy of Sciences)H-Index: 1
#2V. I. Chernov (RAS: Russian Academy of Sciences)H-Index: 3
Last. V. M. Tolmachev (Tomsk Polytechnic University)H-Index: 1
view all 7 authors...
1 CitationsSource
#1Sara S. RinneH-Index: 8
#2Anna Orlova (Tomsk Polytechnic University)H-Index: 53
Last. Vladimir TolmachevH-Index: 61
view all 3 authors...
The human epidermal growth factor receptor family (EGFR-family, other designations: HER family, RTK Class I) is strongly linked to oncogenic transformation. Its members are frequently overexpressed in cancer and have become attractive targets for cancer therapy. To ensure effective patient care, potential responders to HER-targeted therapy need to be identified. Radionuclide molecular imaging can be a key asset for the detection of overexpression of EGFR-family members. It meets the need for rep...
#1Maryam Oroujeni (Uppsala University)H-Index: 7
#2Sara S. Rinne (Uppsala University)H-Index: 8
Last. Vladimir TolmachevH-Index: 61
view all 10 authors...
Radionuclide imaging of HER2 expression in tumours may enable stratification of patients with breast, ovarian, and gastroesophageal cancers for HER2-targeting therapies. A first-generation HER2-binding affibody molecule [99mTc]Tc-ZHER2:V2 demonstrated favorable imaging properties in preclinical studies. Thereafter, the affibody scaffold has been extensively modified, which increased its melting point, improved storage stability, and increased hydrophilicity of the surface. In this study, a secon...
#1Javad Garousi (Uppsala University)H-Index: 13
#2Emma von Witting (KTH: Royal Institute of Technology)H-Index: 4
Last. Sophia Hober (KTH: Royal Institute of Technology)H-Index: 41
view all 11 authors...
Abstract Molecular recognition in targeted therapeutics is typically based on immunoglobulins. Development of engineered scaffold proteins (ESPs) has provided additional opportunities for the development of targeted therapies. ESPs offer inexpensive production in prokaryotic hosts, high stability and convenient approaches to modify their biodistribution. In this study, we demonstrated successful modification of the biodistribution of an ESP known as ADAPT (Albumin-binding domain Derived Affinity...
1 CitationsSource
#1V. Chernov (Research Medical Center)H-Index: 2
#2A. Medvedeva (Research Medical Center)H-Index: 2
view all 6 authors...
#1Anzhelika Vorobyeva (Uppsala University)H-Index: 11
#2Ekaterina Bezverkhniaia (Tomsk Polytechnic University)H-Index: 1
Last. Vladimir Tolmachev (Uppsala University)H-Index: 61
view all 10 authors...
Efficient treatment of disseminated triple-negative breast cancer (TNBC) remains an unmet clinical need. The epithelial cell adhesion molecule (EpCAM) is often overexpressed on the surface of TNBC cells, which makes EpCAM a potential therapeutic target. Radionuclide molecular imaging of EpCAM expression might permit selection of patients for EpCAM-targeting therapies. In this study, we evaluated a scaffold protein, designed ankyrin repeat protein (DARPin) Ec1, for imaging of EpCAM in TNBC. DARPi...
4 CitationsSource
#1Anzhelika VorobyevaH-Index: 11
#2Maryam OroujeniH-Index: 7
Last. Javad GarousiH-Index: 13
view all 8 authors...
Albumin binding domain-Derived Affinity ProTeins (ADAPTs) are small (5 kDa) engineered scaffold proteins that are promising targeting agents for radionuclide-based imaging. A recent clinical study has demonstrated that radiolabeled ADAPTs can efficiently visualize human epidermal growth factor receptor 2 (HER2) expression in breast cancer using SPECT imaging. However, the use of ADAPTs directly labeled with radiometals for targeted radionuclide therapy is limited by their high reabsorption and p...
1 CitationsSource